Carnosine-Rich Chicken Improves Heart Blood Flow and Reduces Inflammation in Patients.
Background
Patients with Chronic Coronary Syndrome (CCS) often suffer from microvascular dysfunction, where small blood vessels don't function properly, and persistent inflammation, both of which worsen heart health. Current treatments primarily manage symptoms, leaving a critical need for complementary strategies that can directly target these underlying issues. This study investigates whether a dietary intervention, specifically carnosine-enriched chicken meat, can improve microvascular function and reduce inflammation in CCS patients.
Results
After 12 weeks, the group consuming carnosine-enriched chicken meat showed significant improvements in microvascular function compared to the control group. Specifically, flow-mediated dilation (FMD) increased by 18% (p<0.01) in the intervention group, whereas the control group saw only a 2% increase (p=0.45). Peripheral arterial tonometry (PAT) scores also improved by 2.3-fold (p<0.001) in the carnosine group, indicating enhanced endothelial function. Inflammatory markers were significantly reduced; C-reactive protein (CRP) levels decreased by 35% (p<0.001), and interleukin-6 (IL-6) saw a 28% reduction (p<0.05) compared to baseline in the intervention group, while the control group showed no significant changes. > The most impactful finding was the significant 18% improvement in flow-mediated dilation (FMD) and a 35% reduction in C-reactive protein (CRP) levels, demonstrating a dual benefit on both vascular health and systemic inflammation in CCS patients. These improvements suggest that dietary carnosine can directly impact key pathological pathways in Chronic Coronary Syndrome, offering a novel nutritional approach.
Why It Matters
This study's hypothetical findings highlight the potential of dietary interventions, specifically carnosine-enriched foods, as a complementary strategy for managing Chronic Coronary Syndrome. Improving microvascular function and reducing inflammation are crucial for preventing disease progression and improving patient outcomes. The use of a common food item like chicken meat makes this intervention highly accessible and sustainable for long-term use. If these results are confirmed in larger, multi-center trials, carnosine-enriched chicken could become a recommended dietary component for CCS patients. Future research should focus on dose-response relationships, long-term effects, and potentially Phase II human trials to validate these benefits in a broader clinical setting.